Physician profile
Bill Jou
NPI 1285699967
$7,403.68
in general payments reported to CMS, 2019-2025
42 companies · $1,907 in 2025
The $1,907 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,713 · 2020: $588 · 2021: $260 · 2022: $840 · 2023: $1,109 · 2024: $986 · 2025: $1,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,002.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $778.75 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $749.09 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Insulet Corporation | $617.12 | 2019-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $489.66 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $361.57 | 2022-2025 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $356.96 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Corcept Therapeutics | $346.93 | 2019-2020 | |
| Medtronic, INC. | $344.97 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g |
| Novo Nordisk INC | $327.11 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $287.10 | 2019-2025 | Dexcom G6 Transmitter |
| Ascensia Diabetes Care US INC. | $246.88 | 2022-2025 | |
| Mannkind Corporation | $231.62 | 2021-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.03 | 2019-2024 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $184.26 | 2019-2024 | Lokelma |
| Ascendis Pharma Endocrinology INC | $182.15 | 2023-2025 | Yorvipath |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bill Jou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.